Investigational new drugs - JoVE Visualize

Showing results (451-460 of 3,716) with videos related to

Pageof 372

Sort By:

Investigational New Drugs|July 1, 1992

Evaluation of in vitro drug screening leads using experimental models of human ovarian cancerK G Louie, T C Hamilton, R H Shoemaker, et al.

Investigational New Drugs|July 1, 1992

Phase II study of amonafide in advanced and recurrent sarcoma patientsR P Perez, S L Nash, R F Ozols, et al.

Investigational New Drugs|November 6, 2004

Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractionsEphraim P Lansky, Wenguo Jiang, Huanbiao Mo, et al.

Investigational New Drugs|November 6, 2004

Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance statusGee-Chen Chang, Kun-Chieh Chen, Tsung-Ying Yang, et al.

Investigational New Drugs|January 1, 1994

Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancerI Redei, F Green, J P Hoffman, et al.

Investigational New Drugs|January 1, 1994

Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinomaT M Law, P Mencel, R J Motzer

Investigational New Drugs|January 1, 1994

Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neckM H Huber, I W Dimery, S E Benner, et al.

Investigational New Drugs|November 1, 1993

Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in miceM C Bissery, C H Nguyen, E Bisagni, et al.

Investigational New Drugs|November 1, 1993

Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemiaC Mazurek, J P Dutcher, E L Schwartz, et al.

Investigational New Drugs|May 1, 1993

Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinomaR M Bukowski, J Young, G Goodman, et al.

Pageof 372

Showing results (451-460 of 3,716) with videos related to

Sort By:

Pageof 372

Investigational New Drugs|July 1, 1992

Evaluation of in vitro drug screening leads using experimental models of human ovarian cancerK G Louie, T C Hamilton, R H Shoemaker, et al.

Investigational New Drugs|July 1, 1992

Phase II study of amonafide in advanced and recurrent sarcoma patientsR P Perez, S L Nash, R F Ozols, et al.

Investigational New Drugs|November 6, 2004

Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractionsEphraim P Lansky, Wenguo Jiang, Huanbiao Mo, et al.

Investigational New Drugs|November 6, 2004

Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance statusGee-Chen Chang, Kun-Chieh Chen, Tsung-Ying Yang, et al.

Investigational New Drugs|January 1, 1994

Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancerI Redei, F Green, J P Hoffman, et al.

Investigational New Drugs|January 1, 1994

Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinomaT M Law, P Mencel, R J Motzer

Investigational New Drugs|January 1, 1994

Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neckM H Huber, I W Dimery, S E Benner, et al.

Investigational New Drugs|November 1, 1993

Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in miceM C Bissery, C H Nguyen, E Bisagni, et al.

Investigational New Drugs|November 1, 1993

Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemiaC Mazurek, J P Dutcher, E L Schwartz, et al.

Investigational New Drugs|May 1, 1993

Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinomaR M Bukowski, J Young, G Goodman, et al.

Pageof 372